Merus (MRUS) Competitors $68.09 -1.49 (-2.14%) Closing price 04:00 PM EasternExtended Trading$68.04 -0.05 (-0.07%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MRUS vs. SMMT, GMAB, ASND, VTRS, RDY, QGEN, BBIO, MRNA, VRNA, and ELANShould you be buying Merus stock or one of its competitors? The main competitors of Merus include Summit Therapeutics (SMMT), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Merus vs. Its Competitors Summit Therapeutics Genmab A/S Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories QIAGEN BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Merus (NASDAQ:MRUS) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk. Do insiders & institutionals believe in MRUS or SMMT? 96.1% of Merus shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 3.7% of Merus shares are held by company insiders. Comparatively, 84.9% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, MRUS or SMMT? Merus has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.02, meaning that its share price is 202% less volatile than the S&P 500. Is MRUS or SMMT more profitable? Summit Therapeutics has a net margin of 0.00% compared to Merus' net margin of -685.64%. Merus' return on equity of -50.28% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Merus-685.64% -50.28% -42.00% Summit Therapeutics N/A -208.64%-181.28% Which has preferable valuation and earnings, MRUS or SMMT? Merus has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMerus$56.23M91.59-$215.33M-$5.50-12.38Summit TherapeuticsN/AN/A-$221.32M-$1.01-18.75 Does the media refer more to MRUS or SMMT? In the previous week, Summit Therapeutics had 20 more articles in the media than Merus. MarketBeat recorded 26 mentions for Summit Therapeutics and 6 mentions for Merus. Merus' average media sentiment score of 1.50 beat Summit Therapeutics' score of 0.86 indicating that Merus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merus 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 9 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer MRUS or SMMT? Merus presently has a consensus price target of $88.75, indicating a potential upside of 30.34%. Summit Therapeutics has a consensus price target of $33.79, indicating a potential upside of 78.38%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Merus 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08Summit Therapeutics 3 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65 SummaryMerus beats Summit Therapeutics on 9 of the 15 factors compared between the two stocks. Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRUS vs. The Competition Export to ExcelMetricMerusMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.15B$3.10B$5.75B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-12.3821.3874.9226.41Price / Sales91.59243.79457.0188.61Price / CashN/A44.4425.8129.91Price / Book7.209.6413.256.28Net Income-$215.33M-$53.20M$3.29B$270.38M7 Day Performance1.34%0.44%0.47%2.70%1 Month Performance1.25%4.26%4.59%5.99%1 Year Performance35.80%9.43%73.41%25.94% Merus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRUSMerus2.806 of 5 stars$68.09-2.1%$88.75+30.3%+38.8%$5.15B$56.23M-12.3837Positive NewsSMMTSummit Therapeutics3.0813 of 5 stars$19.44-25.2%$33.79+73.8%-40.7%$19.30B$700K0.00110Gap DownHigh Trading VolumeGMABGenmab A/S3.9454 of 5 stars$27.54flat$37.60+36.5%+3.4%$17.67B$3.12B16.102,682Positive NewsASNDAscendis Pharma A/S3.1994 of 5 stars$205.22-0.3%$244.36+19.1%+64.0%$12.60B$393.54M0.001,017Positive NewsVTRSViatris1.5976 of 5 stars$10.48-0.2%$10.40-0.8%-14.6%$12.24B$14.74B4.3632,000RDYDr. Reddy's Laboratories2.2893 of 5 stars$14.27-0.5%$16.95+18.8%-8.9%$11.97B$3.81B21.7327,811News CoverageQGENQIAGEN4.4431 of 5 stars$47.62+0.1%$49.69+4.4%+0.5%$10.57B$1.98B20.275,765BBIOBridgeBio Pharma4.4155 of 5 stars$54.29+1.7%$63.35+16.7%+95.6%$10.20B$221.90M0.00400Positive NewsAnalyst ForecastMRNAModerna4.5363 of 5 stars$24.83-1.2%$42.88+72.7%-65.6%$9.78B$3.24B0.005,800VRNAVerona Pharma PLC American Depositary Share2.3184 of 5 stars$106.300.0%$109.00+2.5%+257.4%$9.20B$42.28M0.0030Positive NewsELANElanco Animal Health2.6289 of 5 stars$19.02+3.2%$17.33-8.9%+28.0%$9.16B$4.44B20.489,000Positive News Related Companies and Tools Related Companies Summit Therapeutics Competitors Genmab A/S Competitors Ascendis Pharma A/S Competitors Viatris Competitors Dr. Reddy's Laboratories Competitors QIAGEN Competitors BridgeBio Pharma Competitors Moderna Competitors Verona Pharma PLC American Depositary Share Competitors Elanco Animal Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRUS) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
